Cytokinetics Inc’s filing revealed that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $0.13 million on Dec 16 ’25. In the deal valued at $61.24 per share,2,200 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 138,552 shares worth roughly $8.59 million.
Then, Callos Andrew sold 1,042 shares, generating $68,730 in total proceeds. Upon selling the shares at $65.96, the EVP, Chief Commercial Officer now owns 50,660 shares.
Before that, Callos Andrew sold 52,486 shares. Cytokinetics Inc shares valued at $3,461,452 were divested by the EVP, Chief Commercial Officer at a price of $65.95 per share. As a result of the transaction, Callos Andrew now holds 50,660 shares, worth roughly $3.14 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -0.23% to $62.02. Over the last five days, the stock has gained 0.68%. Cytokinetics Inc shares have risen nearly 23.46% since the year began. Nevertheless, the stocks have risen 31.85% over the past one year. While a 52-week high of $69.33 was reached on 11/28/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 60.85, which if violated will result in even more drops to 59.67. On the upside, there is a resistance level at 62.78. A further resistance level may holdings at 63.53.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-11-28, dropping by -0.84 million shares to a total of 12.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 13.79 million shares. There was a decline of -6.47%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
